Budesonide for swallowing problems in epidermolysis bullosa
Part of Digestive system, Ear, nose & throat, Genetic & congenital, Skin clinical trials.
This trial looks back at patients with epidermolysis bullosa (a condition that makes skin very fragile) who had trouble swallowing and were treated with the drug budesonide. It aims to see if the drug helped improve swallowing after one to three months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have epidermolysis bullosa (dominant or recessive type) and have trouble swallowing that didn't get better with other treatments.
- You have been taking budesonide for at least one month for your swallowing problems.
- Your doctor has written down the type of epidermolysis bullosa you have.
- You are able to say if the treatment helped after 1 and/or 3 months.
- You agree to be part of this study (or your parent/guardian agrees if you are a child).
- You are covered by French social security.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
This study tests whether a daily pill called apremilast can reduce the number of new blisters in people with a genetic form of EBS (epidermolysis bullosa simplex). If you get more than 3 new blisters per day and have a confirmed KRT5 or KRT14 mutation, this trial may be a good fit.
This study tests whether a steroid medication called budesonide can help prevent esophageal strictures (abnormal tightening of the swallowing tube) from returning after a stretching procedure in children who were born with a connection between the esophagus and windpipe that was surgically repaired.
This trial tests a budesonide liquid that targets inflammation in the esophagus, stomach, and duodenum (upper digestive tract) in children with Crohn's disease. It aims to see if this treatment can reduce inflammation in those areas without strong side effects.
This trial studies whether combining a specific diet with an oral steroid called budesonide can calm symptoms in people with mild to moderate ulcerative colitis. It may help reduce inflammation in the colon while building on stable current treatments.
This trial studies whether budesonide extended-release tablets are safe and effective for improving symptoms in children ages 5–17 with active, mild to moderate ulcerative colitis. It also measures how the medicine moves through the body.
Hear when a new Recessive Dystrophic Epidermolysis Bullosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.